Fig. (3) The vimentin concentrations in clinical samples measured by ELISA kits: (A-C) CSB-E08982h (Cusabio Biotech) and (D-F) MBS721933, (MyBioSource). (A) Serum vimentin in patients with lung cancer vs. non-lung cancer. (B) Serum vimentin in patients with NSCLC vs. SCLC. (C) Vimentin in pleural effusions in which cancer cells are present vs. absent. (D) Serum vimentin in patients with lung cancer vs. non-lung cancer. (E): Serum vimentin in patients with NSCLC vs. SCLC. (F): Vimentin in pleural effusions in which cancer cells are present vs. absent.

Back to Article